Elixir Medical's DynamX Bioadaptor restores natural artery function, reducing the risk of future cardiac events.
Washington D.C. – October 28, 2024 – Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant benefit of the ...
Paris – May 21, 2025 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced three-year results from the large 445-patient ...
Elixir Medical's DynamX bioadaptor has been shown to diminish target lesion failure (TLF) by 48% in a landmark clinical trial. Image credit: Jo Panuwat D via Shutterstock.com. Elixir Medical’s ...
Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first interventional technology to ...
The DynamX Bioadaptor is a new class of treatment for Coronary Artery Disease. SINGAPORE, January 28, 2021 /EINPresswire.com/ — Elixir Medical’s 24-Month Clinical ...
(MENAFN- GlobeNewsWire - Nasdaq) Elixir Medical's DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex ...
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- -Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX ® compared to DES- -Significantly lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback